Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Voices From Emerging Markets Expected At Next ICH Steering Committee - APEC Harmonization Center Regulatory Conference

This article was originally published in PharmAsia News

Executive Summary

SEOUL - When ICH was created in 1990, Japan, U.S. and EU were the only participants, but more and more regulatory agencies are adopting variations of ICH guidelines for their own countries. In June, ICH's technical working groups will for the first time be expanded to include regional harmonization initiatives (RHIs), which regulators are calling a "dramatic change" towards global harmonization

You may also be interested in...



Common Language For Regulatory Harmonization Takes Shape In Asia, But Mutual Recognition Unlikely Anytime Soon

Regulators, industry and health care agencies are increasingly using the same language to describe efforts at harmonization for drug approvals and manufacturing. But even though mutual recognition agreements on drug approvals are the “ultimate goal,” getting there in Asia could take a decade or more.

Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference

SEOUL - Korea FDA said it is planning to introduce a set of pharmacovigilance-related policies including the establishment of a national drug safety management center to collect, assess, evaluate and disseminate drug safety information

Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference

SEOUL - Korea FDA said it is planning to introduce a set of pharmacovigilance-related policies including the establishment of a national drug safety management center to collect, assess, evaluate and disseminate drug safety information

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel